Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction
Back to article page
OriginalPaper|Updated:2022-05-13
|
Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction
Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction
Yue Chen, Yu-ying Xu, Hai-jun Jiang, 等. Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction[J/OL]. 1-6.
Yue Chen, Yu-ying Xu, Hai-jun Jiang, et al. Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction[J/OL]. 1-6.
Yue Chen, Yu-ying Xu, Hai-jun Jiang, 等. Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction[J/OL]. 1-6. DOI: 10.1007/s11655-022-3676-7.
Yue Chen, Yu-ying Xu, Hai-jun Jiang, et al. Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction[J/OL]. 1-6. DOI: 10.1007/s11655-022-3676-7.
Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction
Effect of Jianpi Bushen Sequential Formula on Adjuvant Chemotherapy of Colon Cancer: Study Protocol for a Randomized Controlled Trial
相关作者
暂无数据
相关机构
Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medicine Sciences, Beijing, China;Centre for Evidence-Based Chinese Medicine, Beijing University of traditional Chinese Medicine, Beijing, China;Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, USA